Searched over 200M research papers
10 papers analyzed
These studies suggest metformin generally helps prevent or reduce weight gain in various populations, including type 2 diabetic patients, obese pregnant women, and those on antipsychotic medications.
17 papers analyzed
20 papers analyzed
Metformin is a widely used medication primarily prescribed for managing type 2 diabetes. It has been extensively studied for its effects on body weight, particularly in populations at risk of weight gain due to various medical treatments or conditions. This article synthesizes current research to address the question: does metformin cause weight gain?
Research indicates that metformin can prevent weight gain in patients with type 2 diabetes (T2D). A post hoc analysis of the HOME trial demonstrated that patients treated with metformin experienced significantly less weight gain compared to those on a placebo over a 4.3-year period. This effect was not attributed to a reduction in energy intake, suggesting other mechanisms at play.
A review of numerous clinical studies over several decades has shown that metformin often results in weight loss or at least weight neutrality in patients with T2D. This is particularly advantageous as many other antidiabetic treatments tend to promote weight gain.
In a double-blind, placebo-controlled trial involving obese pregnant women without diabetes, metformin administration resulted in significantly lower gestational weight gain compared to placebo. This suggests that metformin can be effective in managing weight during pregnancy, although it did not affect neonatal birth weight.
A retrospective cohort study found that pregnant women with type 2 diabetes or prediabetes who were exposed to metformin had less excess weight gain and a higher rate of weight loss compared to those not exposed to the drug. This indicates that metformin may help achieve appropriate weight gain during pregnancy.
Metformin has been shown to stabilize weight in children and adolescents who experience significant weight gain due to atypical antipsychotic therapy. A 16-week double-blind, placebo-controlled trial found that metformin effectively managed weight gain and improved insulin sensitivity in this population. A systematic review and meta-analysis further confirmed these findings, showing significant weight reduction in children and adolescents treated with metformin while on second-generation antipsychotics.
In adults, metformin has also been effective in reducing weight gain associated with antipsychotic medications. A systematic review and meta-analysis of randomized controlled trials found that metformin significantly reduced body weight in non-diabetic patients treated with atypical antipsychotics. Another study specifically focusing on first-episode schizophrenia patients demonstrated that metformin attenuated olanzapine-induced weight gain and insulin resistance.
The evidence overwhelmingly suggests that metformin does not cause weight gain. Instead, it often prevents weight gain or promotes weight loss in various populations, including those with type 2 diabetes, obese pregnant women, and individuals on antipsychotic medications. These findings highlight metformin's potential as a valuable tool in managing weight-related issues across different patient groups.
Most relevant research papers on this topic